NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its appointment of Suzanne Thornton-Jones, Ph.D. as senior vice president, regulatory affairs. Dr. Thornton-Jones will leverage her expertise to guide Genprex’s regulatory submissions and strategy for its pipeline of gene therapy drug candidates. “We are delighted to welcome Dr. Thornton-Jones to the Genprex team as her strategic regulatory and drug development expertise, including with novel gene therapy products, will be invaluable as we advance our innovative gene therapies to treat cancer and diabetes,” said Rodney Varner, chairman, president and CEO at Genprex. “We look forward to benefitting from Dr. Thornton-Jones’ deep domain experience at this important point in Genprex’s growth, particularly as we advance and expand our clinical development programs in oncology with our REQORSA(R) Immunogene Therapy drug candidate and progress the development of our diabetes gene therapy program toward first-in-human studies. We look forward to Dr. Thornton-Jones’ guidance as we drive these important clinical programs forward.”
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer